SEC Form 4 · accession 0001639637-16-000004
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen L. Smith
Officer — Global Head of R&D and CMO
Period of report
Jun 13, 2016
Accepted (ET)
Jun 15, 2016 · 5:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2,F3 | Jun 13, 2016 | P | 557 | $149.6142 | A | 12,994 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $149.54 to $150.28. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were made.
- F3Includes 38 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2016.